One notable phase 1b trial by Matin et al. explored targeted fibroblast growth factor inhibition, specifically looking at its efficacy in tumors with genetic mutations in fibroblast growth factor receptor 3, which is the most common UTUC mutation [74]. Here, FGFR3 is linked to renal pelvis/ureter urothelial carcinoma.